Bristol Myers Squibb Stock Down 25% Amid Patent Cliff Concerns

Bristol Myers Squibb is trading more than 25% off its high due to a steep patent cliff the company faces. Generic competition caused Revlimid sales to decline by 48.9% to $2.9 billion in 2025, while Sprycel sales dipped 61.7% to $493 million.

More pressing is the looming patent expiration of top sellers Eliquis and Opdivo, which combined for $24.4 billion in sales in 2025, roughly half of total revenue. Those drugs will lose U.S. patent protection between 2027 and 2029, paving the way for generics shortly thereafter.

Bristol Myers Squibb has a growth portfolio of rising drugs, which, excluding Opdivo, grew sales roughly 23% to $16.3 billion in 2025. Cobenfy is a groundbreaking antipsychotic drug for schizophrenia that launched in late 2024. It's now in a phase 3 study for treating psychosis related to Alzheimer's disease. Results are due in 2026, and if ultimately approved, the drug would be the first of its kind.

Estimates indicate that Cobenfy could hit annual sales of $3.4 billion by 2030 if it wins approval from the Food and Drug Administration (FDA).

For now, the patent cliff is a slow slide, not a plunge. Estimates call for sales to decline from $48.2 billion in 2025 to $45.2 billion by the end of 2027. Earnings are expected to be flat in 2026.

Bristol Myers Squibb will pay a dividend, currently 4.2%. The dividend costs less than half of earnings, so it's pretty safe and can endure even a sizable contraction in the business. The stock trades at less than 10 times this year's earnings estimates. There are still risks, such as the possibility that Cobenfy fails its phase 3 study.